Page 2 - Eric Jonasch News Today

/PRNewswire/ -- Vial introduces a new member joining their Oncology CRO Advisory Board. Eric Jonasch, MD, is a Genitourinary Medical Oncology Professor and...

Belzutifan is an important step forward in the treatment of kidney cancer and other neoplasms associated with von Hippel-Lindau disease.

The hypoxia-inducible factor 2α inhibitor belzutifan is active in renal cell carcinoma associated with von Hippel-Lindau (VHL) disease.

Patients with von Hippel-Lindau face a high risk of renal cell carcinoma and other cancers, which often require multiple surgeries. A new drug may change the course of the disease.

Belzutifan might serve as an alternative for or a complement to surgery Belzutifan (MK-6482), a novel oral agent that targets germline pathogenic variants in the von Hippel-Lindau (VHL) gene that gives rise to VHL disease, demonstrated robust clinical activity and a very mild adverse event (AE) profile in VHL patients with renal cell carcinoma, a

Even higher response rate seen among patients' pancreatic lesions

WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not Requiring Immediate Surgery WELIREG Expands Merck’s Oncology Portfolio as the First and Only Systemic Therapy Approved for These Patients With VHL Disease Merck known as MSD outside the United States and Canada, today ...

Share this article PLYMOUTH MEETING, Pa., April 13, 2021 /PRNewswire/ -- The April 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network publishes new research from Memorial Sloan Kettering Cancer Center (MSK) and Gustave Roussy Institute, which suggests that baseline brain imaging should be considered in most patients with metastatic kidney cancer. The researchers studied 1,689 patients with metastatic renal cell carcinoma (mRCC) who had been considered for clinical tria...

2021 Research Grant Recipients Announced by the VHL Alliance Global Research Program Supports Curing Cancer through VHL News provided by Share this article Share this article BOSTON, Jan. 19, 2021 /PRNewswire/ -- The VHL Alliance (VHLA) today announced the 2021 recipients of the VHLA Competitive Research Grant Program.  This year, three grantees were chosen. Scientists are increasingly aware that curing von Hippel-Lindau disease, a genetic form of cancer – is a key step to curing cancer, le...